Join your oncology nurse colleagues in attending this non-CNE promotional event sponsored by Pfizer Inc, spotlighting INLYTA® (axitinib) tablets as a treatment for patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
During this presentation, you will learn about the therapy, the indication, the product mechanism of action, clinical study results, and the benefits and risks of treatment. You will also learn about the importance of adherence to oral medication.